Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
RVMD

RVMD - REVOLUTION Medicines Inc Stock Price, Fair Value and News

39.99USD+0.97 (+2.49%)Market Closed

Market Summary

RVMD
USD39.99+0.97
Market Closed
2.49%

RVMD Alerts

  • 1 major insider sales recently.

RVMD Stock Price

View Fullscreen

RVMD RSI Chart

RVMD Valuation

Market Cap

6.6B

Price/Earnings (Trailing)

-13.62

Price/Sales (Trailing)

569.76

EV/EBITDA

-13.08

Price/Free Cashflow

-14.41

RVMD Price/Sales (Trailing)

RVMD Profitability

EBT Margin

-4212.40%

Return on Equity

-28.07%

Return on Assets

-25.38%

Free Cashflow Yield

-6.94%

RVMD Fundamentals

RVMD Revenue

Revenue (TTM)

11.6M

Rev. Growth (Yr)

-95.16%

Rev. Growth (Qtr)

-100%

RVMD Earnings

Earnings (TTM)

-484.3M

Earnings Growth (Yr)

-70.35%

Earnings Growth (Qtr)

28.19%

Breaking Down RVMD Revenue

Last 7 days

-1.7%

Last 30 days

7.6%

Last 90 days

25.1%

Trailing 12 Months

56.3%

How does RVMD drawdown profile look like?

RVMD Financial Health

Current Ratio

18.45

RVMD Investor Care

Shares Dilution (1Y)

55.19%

Diluted EPS (TTM)

-3.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202334.8M29.5M26.2M11.6M
202226.8M27.3M29.5M35.4M
202141.6M40.2M28.7M29.4M
202048.4M46.2M46.3M43.0M
201927.6M35.1M42.6M50.0M
201800020.2M

Tracking the Latest Insider Buys and Sells of REVOLUTION Medicines Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 03, 2024
goldsmith mark a
sold
-299,942
39.9923
-7,500
see remarks
Jun 03, 2024
goldsmith mark a
acquired
30,675
4.09
7,500
see remarks
May 21, 2024
cislini jeff
sold
-58,670
39.1139
-1,500
general counsel
May 03, 2024
anders jack
acquired
26,800
2.68
10,000
chief financial officer
May 03, 2024
anders jack
sold
-400,260
40.026
-10,000
chief financial officer
Apr 10, 2024
patel sushil
acquired
36,204
16.8
2,155
-
Apr 10, 2024
patel sushil
sold
-79,735
37.00
-2,155
-
Apr 10, 2024
goldsmith mark a
sold
-266,122
35.4829
-7,500
see remarks
Apr 10, 2024
goldsmith mark a
sold
-353,346
35.3345
-10,000
see remarks
Mar 27, 2024
cislini jeff
sold
-46,481
30.9873
-1,500
general counsel

1–10 of 50

Which funds bought or sold RVMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
119,000
1,577,000
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-6.02
64,000
1,205,000
0.01%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
added
11.44
48,765,700
241,979,000
1.10%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
unchanged
-
-20,414
19,214
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
67.03
476,661
1,019,660
0.13%
May 17, 2024
Artal Group S.A.
reduced
-22.25
-6,139,940
42,500,100
1.08%
May 16, 2024
Mubadala Investment Co PJSC
unchanged
-
986,900
8,959,940
0.04%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-7.65
123,641
3,396,170
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-34.02
-1,455,210
4,172,720
-%
May 16, 2024
COMERICA BANK
new
-
18,159
18,159
-%

1–10 of 45

Are Funds Buying or Selling RVMD?

Are funds buying RVMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RVMD
No. of Funds

Unveiling REVOLUTION Medicines Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
biotechnology value fund l p
1.9%
3,079,232
SC 13G/A
Feb 14, 2024
ecor1 capital, llc
0.1%
132,579
SC 13G/A
Feb 13, 2024
bb biotech ag
3.1%
5,046,700
SC 13G/A
Feb 13, 2024
vanguard group inc
8.93%
14,634,391
SC 13G/A
Feb 12, 2024
farallon capital partners, l.p.
0.2%
329,602
SC 13G/A
Feb 09, 2024
column group iii, lp
0%
0
SC 13G/A
Feb 08, 2024
wellington management group llp
9.09%
14,882,086
SC 13G/A
Jan 26, 2024
blackrock inc.
7.9%
12,954,314
SC 13G/A
Nov 09, 2023
farallon capital partners, l.p.
0.3%
291,600
SC 13G
Nov 09, 2023
wellington management group llp
12.99%
14,219,430
SC 13G/A

Recent SEC filings of REVOLUTION Medicines Inc

View All Filings
Date Filed Form Type Document
Jun 05, 2024
4
Insider Trading
Jun 03, 2024
144
Notice of Insider Sale Intent
May 22, 2024
4
Insider Trading
May 21, 2024
144
Notice of Insider Sale Intent
May 08, 2024
S-3ASR
S-3ASR
May 08, 2024
10-Q
Quarterly Report
May 08, 2024
8-K
Current Report
May 03, 2024
144
Notice of Insider Sale Intent
May 03, 2024
4
Insider Trading
Apr 26, 2024
UPLOAD
UPLOAD

Peers (Alternatives to REVOLUTION Medicines Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
56.6B
6.8B
17.55% 15.42%
-9.49
8.27
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.1B
2.0B
6.10% -19.49%
-60.58
10.04
75.20% 68.82%
16.1B
2.5B
5.03% -10.77%
78.14
6.5
13.74% 186.89%
13.5B
3.8B
4.06% -3.24%
18.05
3.57
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.63% 71.22%
-9.82
48.09
54.84% -28.31%
5.2B
524.1M
-1.19% -54.45%
-12.36
9.84
394.93% 39.61%
3.4B
251.0M
-5.41% -4.45%
-11.47
13.54
73.58% -86.73%
3.2B
240.7M
16.82% -26.89%
-6.77
12.77
-1.03% -213.92%
2.5B
813.8M
1.25% -38.59%
-1.5K
3.12
56.43% 98.83%
2.2B
996.6M
20.98% 97.26%
-5.59
2.23
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-4.75% 32.39%
28.02
4.44
60.38% -34.49%
547.7M
881.7K
19.55% 492.49%
-16.22
481.06
-77.61% 33.36%
245.6M
4.2M
-16.55% 51.92%
-1.97
59.05
-66.30% 48.24%
22.0M
2.1M
40.11% 239.32%
-0.95
7.61
-13.45% 69.54%

REVOLUTION Medicines Inc News

Latest updates
MarketBeat38 hours ago
InvestorPlace08 May 202407:00 am
The Motley Fool7 months ago

REVOLUTION Medicines Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-100.0%-742,000-3,824,0007,014,00015,330,0003,356,0009,116,0007,578,0009,460,0001,101,0008,698,00010,131,0008,751,00012,661,00010,025,00011,546,00012,088,00012,506,00012,281,00013,166,000
Operating Expenses-22.1%140,859,000180,725,000123,248,000112,621,00082,171,00077,037,50079,889,00071,205,00065,527,00062,373,00054,264,00053,233,00047,528,00042,831,00040,212,00038,009,00032,628,00031,652,00026,065,00022,842,00023,602,000
  S&GA Expenses-29.2%22,838,00032,244,00015,513,00014,640,00013,224,00010,910,50010,434,00010,204,0009,037,0008,692,0007,791,0007,297,0006,670,0005,825,0005,341,0005,091,0005,171,0004,162,0003,103,0002,725,0002,416,000
  R&D Expenses-20.5%118,021,000148,481,000107,735,00097,981,00068,947,00066,127,00069,455,00061,001,00056,490,00053,681,00046,473,00045,936,00040,858,00037,006,00034,871,00032,918,00027,457,00027,490,00022,962,00020,117,00021,186,000
EBITDA Margin-10.9%-41.66-37.55-12.63-9.89-7.33-6.93-8.18-8.11-7.61-6.26-5.76-3.47---------
Interest Expenses-------------12,00014,00017,00019,00021,000----
Income Taxes-100.0%-343,000-3,867,000---123,000-297,000------362,000--58,000-675,000----
Earnings Before Taxes28.0%-116,003,000-161,194,000-112,301,000-98,298,000-68,098,000-56,630,000-73,626,000-61,222,000-57,647,000-52,676,000-52,940,000-44,299,000-37,176,000-33,842,000-27,221,000-27,273,000-20,194,000-18,969,000-12,818,000-10,119,000-10,131,000
EBT Margin-10.9%-42.12-37.99-12.81-10.05-7.46-7.04-8.31-8.24-7.73-6.37-5.87-3.54---------
Net Income28.2%-116,003,000-161,537,000-108,434,000-98,298,000-68,098,000-56,507,000-73,329,000-61,222,000-57,647,000-52,676,000-52,940,000-44,299,000-37,176,000-34,204,000-27,221,000-27,215,000-19,519,000-14,596,000-12,818,000-10,119,000-10,131,000
Net Income Margin-11.0%-41.82-37.68-12.66-10.03-7.44-7.03-8.30-8.24-7.73-6.37-5.88-3.55---------
Free Cashflow-33.2%-163,727,000-122,880,000-103,032,000-68,240,000-64,149,000-64,664,000-55,262,000-58,242,000-57,049,000-40,448,000-37,042,000-35,393,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets-7.4%1,9082,0629841,0741,073812826633683738735774812567595454454221
  Current Assets-8.0%1,7291,879824922923660675483534590624661697454483340362134
    Cash Equivalents-58.6%28869635838042716117910698.0010812919635210465.0024.0018317.00
  Net PPE3.6%24.0023.0020.0020.0019.0019.0018.0016.0013.0012.0010.0011.0011.009.007.007.007.007.00
  Goodwill0%15.0015.0015.0015.0015.0015.0015.0015.0015.0015.0015.0015.0015.0015.0015.0015.0015.0015.00
Liabilities-22.3%18323614714312112714413413213597.0089.0089.0093.0090.0093.0069.0068.00
  Current Liabilities-34.8%94.0014486.0078.0055.0062.0073.0064.0057.0060.0052.0046.0044.0047.0042.0044.0042.0043.00
Shareholder's Equity-5.5%1,7251,826837931952685681499551603638685723475505360385-
  Retained Earnings-14.3%-1,300-1,137-976-867-769-701-644-571-510-452-399-347-302-265-231-204-176-157
  Additional Paid-In Capital0.6%2,9802,9631,8141,8001,7221,3881,3291,0721,0631,0561,0381,0321,0257407365645625.00
Shares Outstanding0.1%16516510910995.0090.0078.0074.0074.0073.0074.0072.00------
Float----2,757---1,231---1,956---1,107--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-33.2%-160-120-100-67.12-62.39-61.79-51.74-55.72-55.16-39.26-36.59-34.08-37.25-25.03-27.02-19.99-28.02-11.65-13.86-11.50-12.60
  Share Based Compensation-36.3%16.0025.0014.0013.0010.008.008.008.007.006.006.005.003.003.003.002.002.001.001.001.000.00
Cashflow From Investing34.8%-247-38077.00-43.544.00-7.10-12362.0044.009.00-30.18-1222.0063.00-100-136-59.728.00-59.80-55.956.00
Cashflow From Financing-99.9%1.008391.0065.0032451.002481.000.0011.000.001.002821.00169-1.34254-1.5310.0090.000.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

RVMD Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 0$ 7,014
Revenue, Product and Service [Extensible Enumeration]Collaboration Revenue MemberCollaboration Revenue Member
Operating expenses:  
Research and development$ 118,021$ 68,947
General and administrative22,83813,224
Total operating expenses140,85982,171
Loss from operations(140,859)(75,157)
Other income, net:  
Interest income23,7607,059
Other expense, net(2,809)0
Change in fair value of warrant liabilities and contingent earn-out shares3,9050
Total other income, net24,8567,059
Loss before income taxes(116,003)(68,098)
Benefit from income taxes00
Net loss$ (116,003)$ (68,098)
Net loss per share attributable to common stockholders, basic$ (0.7)$ (0.72)
Net loss per share attributable to common stockholders, diluted$ (0.7)$ (0.72)
Weighted-average common shares used to compute net loss per share, basic164,729,20094,831,979
Weighted-average common shares used to compute net loss per share, diluted164,729,20094,831,979
Comprehensive loss:  
Net Income (Loss)$ (116,003)$ (68,098)
Other comprehensive gain (loss):  
Unrealized gain (loss) on investments, net(1,742)1,224
Comprehensive loss$ (117,745)$ (66,874)

RVMD Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 288,432$ 696,148
Marketable securities1,415,1081,156,807
Accounts receivable01,254
Prepaid expenses and other current assets25,66225,072
Total current assets1,729,2021,879,281
Property and equipment, net23,69722,865
Operating lease right-of-use asset76,19377,149
Intangible assets, net57,47257,739
Goodwill14,60814,608
Restricted cash3,0313,031
Other noncurrent assets4,1597,032
Total assets1,908,3622,061,705
Current liabilities:  
Accounts payable32,37961,788
Accrued expenses and other current liabilities53,17574,694
Operating lease liability, current8,1697,369
Total current liabilities93,723143,851
Deferred tax liability3,1153,115
Operating lease liability, noncurrent79,86080,575
Warrant liabilities3,1576,512
Other noncurrent liabilities3,0401,458
Total liabilities182,895235,511
Commitments and contingencies (Note 8)
Stockholders' equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; none issued and outstanding at March 31, 2024 and December 31, 2023, respectively00
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 170,473,067 and 170,234,594 shares issued as of March 31, 2024 and December 31, 2023, respectively; 164,913,014 and 164,674,594 shares outstanding as of March 31, 2024 and December 31, 2023, respectively1616
Additional paid-in capital2,980,3602,963,342
Accumulated other comprehensive income (loss)(1,198)544
Accumulated deficit(1,253,711)(1,137,708)
Total stockholders' equity1,725,4671,826,194
Total liabilities and stockholders' equity$ 1,908,362$ 2,061,705
RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
 CEO
 WEBSITErevmed.com
 INDUSTRYBiotechnology
 EMPLOYEES292

REVOLUTION Medicines Inc Frequently Asked Questions


What is the ticker symbol for REVOLUTION Medicines Inc? What does RVMD stand for in stocks?

RVMD is the stock ticker symbol of REVOLUTION Medicines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of REVOLUTION Medicines Inc (RVMD)?

As of Wed Jun 12 2024, market cap of REVOLUTION Medicines Inc is 6.6 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RVMD stock?

You can check RVMD's fair value in chart for subscribers.

What is the fair value of RVMD stock?

You can check RVMD's fair value in chart for subscribers. The fair value of REVOLUTION Medicines Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of REVOLUTION Medicines Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RVMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is REVOLUTION Medicines Inc a good stock to buy?

The fair value guage provides a quick view whether RVMD is over valued or under valued. Whether REVOLUTION Medicines Inc is cheap or expensive depends on the assumptions which impact REVOLUTION Medicines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RVMD.

What is REVOLUTION Medicines Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, RVMD's PE ratio (Price to Earnings) is -13.62 and Price to Sales (PS) ratio is 569.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RVMD PE ratio will change depending on the future growth rate expectations of investors.